Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
1,34 USD | +0,75% | -1,47% | +8,06% |
Attività
Numero di dipendenti: 167
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100,0
%
| 292 | 100,0 % | 195 | 100,0 % | -33,46% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 292 | 100,0 % | 195 | 100,0 % | -33,46% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
John Butler
CEO | Chief Executive Officer | 59 | 01/07/13 |
Tracey Vetterick
ADM | Chief Administrative Officer | - | 01/04/22 |
Michel Dahan
COO | Chief Operating Officer | 45 | 01/01/13 |
Steven Burke
CTO | Chief Tech/Sci/R&D Officer | 63 | 17/06/19 |
Chief Tech/Sci/R&D Officer | - | - | |
Corporate Officer/Principal | - | - | |
Carolyn Rucci
LAW | General Counsel | - | 01/01/21 |
Meredith Bowman
HRO | Human Resources Officer | - | 01/05/22 |
Christian Barnes
PRN | Corporate Officer/Principal | - | - |
Nicholas Grund
PRN | Corporate Officer/Principal | 54 | 09/01 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Michael Rogers
BRD | Director/Board Member | 64 | 12/12/18 |
Adrian Adams
CHM | Chairman | 73 | 12/12/18 |
Director/Board Member | 65 | 16/02/21 | |
John Butler
CEO | Chief Executive Officer | 59 | 01/07/13 |
Steven Gilman
BRD | Director/Board Member | 71 | 12/12/18 |
Ronald Frieson
BRD | Director/Board Member | 65 | 01/11/21 |
Cynthia Smith
BRD | Director/Board Member | 55 | 28/08/18 |
Myles Wolf
BRD | Director/Board Member | 53 | 06/04/20 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 209 595 254 | 188 221 008 ( 89,80 %) | 0 | 89,80 % |
Coordinate società
Akebia Therapeutics, Inc.
245 First Street Suite 1400
02142, Cambridge
+617 871 2098
http://www.akebia.comSettore
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+8,06% | 281 Mln | |
-2,31% | 103 Mrd | |
+0,56% | 95,28 Mrd | |
+1,69% | 22,15 Mrd | |
-17,37% | 21,02 Mrd | |
-9,30% | 18,15 Mrd | |
-41,01% | 16,74 Mrd | |
-14,85% | 16,05 Mrd | |
+3,21% | 13,68 Mrd | |
+33,54% | 12,17 Mrd |
- Borsa valori
- Azioni
- Azione AKBA
- Società Akebia Therapeutics, Inc.